Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population

被引：15

作者：

Leach, Amanda J. ^{[1
]}

Morris, Peter S. ^{[1
,2
]}

Mackenzie, Grant ^{[1
]}

McDonnell, Joseph ^{[1
]}

Balloch, Anne ^{[3
]}

Carapetis, Jonathan ^{[1
,2
]}

Tang, Mimi ^{[3
]}

机构：

[1] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia

[2] Flinders Univ S Australia, NT Clin Sch, Darwin, NT, Australia

[3] Murdoch Childrens Res Inst, Melbourne, Vic, Australia

来源：

VACCINE | 2008年 / 26卷 / 31期

关键词：

immunogenicity; 16; serotypes; pneumococcal vaccines; high-risk population;

D O I：

10.1016/j.vaccine.2008.05.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2,4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001. Methods: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA. Results: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were > 1.95 mu g/ml and at least 89% of infants had IgG > 035 mu g/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was > 035 mu g/ml for more than 96% infants (> 1.3 mu g/ml for at least 70%), and IgG to non-7PCV serotypes was > 035 mu g/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%). Conclusion: 7PCV and 23PPV are immunogenic in this population. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：3885 / 3891

页数：7

共 50 条

[21] Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes
Grant, Lindsay R.
O'Brien, Sarah E.
Burbidge, Polly
Haston, Mitch
Zancolli, Marta
Cowell, Lucy
Johnson, Marina
Weatherholtz, Robert C.
Reid, Raymond
Santosham, Mathuram
O'Brien, Katherine L.
Goldblatt, David
PLOS ONE, 2013, 8 (09):
[22] Pneumococcal vaccination underused in elderly and high-risk groups
Drugs & Therapy Perspectives, 1998, 11 (5) : 13 - 16
[23] BACAMPICILLIN TREATMENT OF PNEUMOCOCCAL PNEUMONIA IN HIGH-RISK PATIENTS
CAMPBELL, S
BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1983, 59 (05) : 497 - 504
[24] Prevention of pneumococcal disease in high-risk pediatric groups
Pelton, SI
Santosham, M
Van Beneden, C
Black, S
AMERICAN JOURNAL OF MANAGED CARE, 1999, 5 (17): : S1004 - S1009
[25] Revaccination of high-risk adults with pneumococcal polysaccharide vaccine
Nichol, KL
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03): : 280 - 281
[26] Pneumococcal Vaccination in High-Risk Pediatric Nephrology Patients
Gefen, Ashley M.
Basalely, Abby M.
Balamohan, Archana
Frank, Rachel
Moravec, Megan
Fassano, Jessica
Rajan, Sujatha
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 617 - 617
[27] A High-Risk Population Revealed
Zima, Bonnie T.
PSYCHIATRIC SERVICES, 2011, 62 (06) : 585 - 585
[28] Unique Uses of SPY: High-risk Facelift
Kislevitz, Mikaela L.
Lu, Karen B.
Sanniec, Kyle
Amirlak, Bardia
PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2019, 7 (06) : E2183
[29] Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
Sikjaer, Melina Gade
Pedersen, Andreas Arnholdt
Wik, Mari Stenvold
Stensholt, Synne Smith
Hilberg, Ole
Lokke, Anders
EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2023, 10 (01):
[30] Providing Pneumococcal Vaccines Reduces the Risk of Serious Infections From Pneumococcal Pneumonia. We Should Consider a Simplified Immunization Schedule
Almasry, Mazen
Caldera, Freddy
CROHNS & COLITIS 360, 2023, 5 (04)

← 1 2 3 4 5 →